ImmPACT Bio Closes $111 Million Series B Financing, Names New Board Chair and New President and CEO, and Updates on Phase 1 Clinical Study in Relapsed/Refractory B-cell Non-Hodgkin’s Lymphoma

January 20, 2022 Los Angeles Biotechnology Network News Los Angeles Biotech News Comments Off on ImmPACT Bio Closes $111 Million Series B Financing, Names New Board Chair and New President and CEO, and Updates on Phase 1 Clinical Study in Relapsed/Refractory B-cell Non-Hodgkin’s Lymphoma

CAMARILLO, Calif.: CAMARILLO, Calif., Jan. 20, 2022 /PRNewswire/ — ImmPACT Bio USA, Inc. ("ImmPACT Bio"), a clinical-stage company developing transformative logic-gate based chimeric antigen receptor (CAR) T-cell therapies for treating cancer, today announced it has closed $111 million in Series B financing, led by venBio Partners along with co-leads Foresite…